Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.14459 http://scihub22266oqcxt.onion/10.1111/bcp.14459 32639062!ä!32639062 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Clin+Pharmacol 2021 ; 87 (3): 1533-1540 Nephropedia Template TP {{tp|p=32639062|t=2021. Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 |pdf=|usr=}}{{32639062}} gab.com Text Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32639062 #FOAvip Given its approval for the treatment of cytokine release syndrome, tocilizumab is under investigation in severe coronavirus disease-2019. To characterize serious adverse events (AEs) with tocilizumab, we queried the worldwide FDA Adverse Event Reporting System and performed disproportionality analysis, selecting only designated medical events (DMEs) where tocilizumab was reported as suspect, with a focus on hepatic reactions. The reporting odds ratios (RORs) were calculated, deemed significant by a lower limit of the 95% confidence interval (LL 95% CI) > 1. A total of 2,433 reports of DMEs were recorded with tocilizumab, mainly in rheumatic diseases. Statistically significant RORs emerged for 13 DMEs, with drug-induced liver injury (n = 91; LL 95% CI 3.07), pancreatitis (151; 1.41), and pulmonary fibrosis (222; 7.21) as unpredictable AEs. A total of 174 cases of liver-related DMEs were retrieved (proportion of deaths = 18.4%), with median onset of 27.5 days. These serious unpredictable reactions occurring in chronic real-world tocilizumab use may support patient care and monitoring of ongoing clinical trials. Twit Text FOAVip Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32639062 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32639062 #FOAvip English Wikipedia <ref>{{Cite pmid|32639062}}</ref> Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 #MMPMID32639062 Gatti M; Fusaroli M; Caraceni P; Poluzzi E; De Ponti F; Raschi E Br J Clin Pharmacol 2021[Mar]; 87 (3): 1533-1540 PMID32639062show ga Given its approval for the treatment of cytokine release syndrome, tocilizumab is under investigation in severe coronavirus disease-2019. To characterize serious adverse events (AEs) with tocilizumab, we queried the worldwide FDA Adverse Event Reporting System and performed disproportionality analysis, selecting only designated medical events (DMEs) where tocilizumab was reported as suspect, with a focus on hepatic reactions. The reporting odds ratios (RORs) were calculated, deemed significant by a lower limit of the 95% confidence interval (LL 95% CI) > 1. A total of 2,433 reports of DMEs were recorded with tocilizumab, mainly in rheumatic diseases. Statistically significant RORs emerged for 13 DMEs, with drug-induced liver injury (n = 91; LL 95% CI 3.07), pancreatitis (151; 1.41), and pulmonary fibrosis (222; 7.21) as unpredictable AEs. A total of 174 cases of liver-related DMEs were retrieved (proportion of deaths = 18.4%), with median onset of 27.5 days. These serious unpredictable reactions occurring in chronic real-world tocilizumab use may support patient care and monitoring of ongoing clinical trials. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Adverse Drug Reaction Reporting Systems[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use[MESH] |COVID-19/*complications[MESH] |Chemical and Drug Induced Liver Injury/epidemiology[MESH] |Cytokine Release Syndrome/drug therapy/etiology[MESH] |Databases, Factual[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Monitoring, Physiologic[MESH] |Odds Ratio[MESH] |Pancreatitis/chemically induced/epidemiology[MESH] |Pharmacovigilance[MESH] |Pulmonary Fibrosis/chemically induced/epidemiology[MESH] |Retrospective Studies[MESH] |United States[MESH] |United States Food and Drug Administration[MESH]Serious adverse events with tocilizumab: Pharmacovigilance as an aid t(epmc).pdf DeepDyve Pubget Overpricing